Gregory Young β€” investor profile photo

Gregory Young

Venture Capital and Private Equity Investor

πŸ“ United StatesπŸ”„ Updated November 2026πŸ’Ό 2 investmentsπŸ“… 17 years investingπŸ—“ Last invested Aug 2010
Angel investor🌍 United States
2
Total investments
1
Early stage
0
Mid stage
0
Late stage
17y
Years active

Portfolio

1 investments Β· sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Dec 2009
PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the HYDROS Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. Our proprietary HYDROS Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience.
Experience Β· 2 entries
All (2)
Investments (2)
2010
Arqos Surgical, Inc.
Investor
Aug 2010
2009
Investor
Dec 2009
PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the HYDROS Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. Our proprietary HYDROS Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience.
Investor lists
Lists that match Gregory's portfolio